Tom Isett, iBio CEO
Texas CDMO is cutting 60% of staff as focus shifts to drug discovery, in-house candidates
In September, iBio paid a very affordable price to gain access to an AI-based platform and new therapeutic candidates from the startup RubrYc as …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
